ICU MEDICAL INC (ICUI)
Sector: Health Care
2026 Annual Meeting Analysis
ICU MEDICAL INC · Meeting: May 13, 2026
Directors FOR
0
Directors AGAINST
7
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
As CEO and Chairman since 2014, Mr. Jain has full tenure overlap with a severe stock decline: ICUI's 3-year return of -24.9% trails the IHI medical devices ETF (the applicable benchmark per policy) by 42.8 percentage points, well above the 30-point trigger threshold for companies with negative absolute returns; the 5-year return of -39.8% provides no mitigating offset, confirming sustained underperformance rather than a temporary dip.
Mr. Greenberg has served as a director since 2015, giving him full overlap with the underperformance period; ICUI's 3-year price return of -24.9% lags the IHI ETF by 42.8 percentage points, exceeding the 30-point trigger for negative-TSR companies, and the 5-year return of -39.8% provides no mitigating long-term track record.
Ms. Finney has served since January 2016 and has full overlap with the underperformance period; ICUI's 3-year return of -24.9% trails the IHI ETF by 42.8 percentage points, well above the 30-point trigger, and the 5-year return of -39.8% confirms the underperformance is sustained, not transient.
Mr. Hoffmeister has served since January 2018, well beyond the 24-month new-director exemption, giving him substantial overlap with the underperformance period; ICUI's 3-year return of -24.9% trails the IHI ETF by 42.8 percentage points, exceeding the 30-point trigger, and the 5-year return equally negative provides no mitigant.
Mr. Abbey has served since January 2018, giving him full overlap with the underperformance period; ICUI's 3-year return of -24.9% trails the IHI ETF by 42.8 percentage points, well above the 30-point trigger for negative-TSR companies, and the 5-year return of -39.8% confirms sustained underperformance.
Ms. Hernandez joined in July 2021, which is more than 24 months before the current vote and therefore outside the new-director exemption; ICUI's 3-year return of -24.9% trails the IHI ETF by 42.8 percentage points, exceeding the 30-point trigger, and the 5-year return of -39.8% provides no mitigating long-term offset, though it is noted she joined during a period when underperformance was already developing.
Ms. Kennedy joined in December 2021, which is more than 24 months before the current vote and therefore outside the new-director exemption; ICUI's 3-year return of -24.9% trails the IHI ETF by 42.8 percentage points, exceeding the 30-point trigger for negative-TSR companies, and the 5-year return of -39.8% provides no long-term offset to mitigate the finding, though it is noted she joined during an already-underperforming period.
For Analysis
The TSR underperformance trigger fires against all seven directors. ICUI uses IHI (iShares U.S. Medical Devices ETF) as the applicable benchmark per policy for medical device companies. ICUI's 3-year price return of -24.9% trails IHI's 3-year return of +17.9% by 42.8 percentage points, which exceeds the 30-point threshold applicable to companies with negative absolute 3-year returns. The 5-year TSR of -39.8% provides no mitigating offset — the 5-year underperformance is equally severe — so the vote is not downgraded to FOR under the 5-year mitigant rule. A vote AGAINST all seven directors is warranted based on sustained, material stock underperformance relative to sector peers under the current board's oversight.
Say on Pay
✓ FORCEO
Vivek Jain
Total Comp
$6,452,042
Prior Support
95.9%%
The CEO's total compensation of $6.45 million for fiscal 2025 is reasonable for a CEO of a $3 billion medical device company, with base salary of $775,000 held flat since 2022 and below peer median per the proxy's own disclosure. Pay mix is strongly variable — approximately 86% of target total direct compensation for named executive officers is variable, consisting of performance-based cash bonuses and equity awards (both time-based and performance stock awards with 3-year performance periods tied to Adjusted EBITDA and revenue growth), well above the 50-60% policy threshold. While ICUI's stock has underperformed over 3 years, the incentive structure is genuinely performance-linked with meaningful conditions that can result in zero payout at threshold, actual performance stock awards vested at 117% and 250% based on operational metrics, and the prior year's say-on-pay vote received approximately 96% shareholder support indicating strong investor alignment with the compensation framework.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
18 yrs
Audit Fees
N/A
Non-Audit Fees
N/A
Deloitte has served as ICUI's auditor since March 2008, approximately 18 years, which is below the 25-year tenure threshold that would trigger a No vote; the fee table extracted from the filing does not include numeric audit fee and non-audit fee figures in a format that allows ratio calculation, but no flags suggesting excessive non-audit fees or independence concerns are present in the proxy; Deloitte is a Big 4 firm appropriate for a $3 billion public company, and no material restatements attributable to audit failure are disclosed.
Stockholder Proposals
3 proposals submitted by shareholders
Proposal 4
Vote to Approve Amendments to the Company's Amended and Restated Certificate of Incorporation to Adopt Simple Majority Voting Provisions
This is a board-proposed charter amendment directly responding to a shareholder proposal that passed at the 2025 annual meeting, replacing supermajority voting requirements (two-thirds of outstanding shares) for director removal and related provisions with a simple majority standard. Eliminating supermajority vote requirements is a mainstream governance improvement that makes it easier for shareholders to exercise their rights and reduces entrenchment — the policy strongly supports such changes. The board's decision to implement this change after initially opposing it reflects appropriate responsiveness to shareholders.
Proposal 5
Vote to Approve Amendments to the Company's Amended and Restated Certificate of Incorporation to Adopt a Stockholder Right to Call Special Meetings at an Ownership Threshold of 25%
This board-proposed charter amendment would create a new right for shareholders owning at least 25% of voting power to call a special meeting — a genuine improvement from the current state where only the board, chairman, or president can call special meetings. Giving shareholders a meaningful ability to convene a meeting between annual meetings is a positive governance step that increases accountability. The 25% threshold is market-standard (approximately 37.6% of S&P 500 companies with such a right use 25% or higher), and while a lower threshold would be more permissive, the improvement from zero shareholder right to a 25% right is substantial and worth supporting.
Proposal 7
Advisory Vote on a Stockholder Proposal to Establish a 10% Stockholder Special Meeting Right
John Chevedden is a well-known individual governance activist whose proposals on shareholder rights deserve serious consideration, and his concerns about ICUI's stock decline and regulatory issues are legitimate. However, the company is simultaneously putting Proposal 5 to a binding vote to implement a 25% special meeting threshold — an actual, self-executing charter amendment — which constitutes meaningful partial remediation of the core concern. Moreover, the board has explicitly stated that if both proposals pass, it will implement the 25% threshold rather than the 10% threshold, meaning a vote for Proposal 7 while Proposal 5 also passes would be futile. Supporting the binding 25% right in Proposal 5 is the more effective path to shareholder empowerment; voting for this advisory 10% proposal in addition would not achieve a lower threshold given the board's stated intent.
Overall Assessment
ICUI's 2026 annual meeting ballot presents seven director elections, an auditor ratification, a say-on-pay vote, two binding charter amendments improving governance, an adjournment proposal, and one stockholder proposal on special meeting thresholds. The dominant issue is severe stock underperformance — ICUI's 3-year return of -24.9% trails the IHI medical devices ETF by 42.8 percentage points with no 5-year offset — triggering an AGAINST vote on all seven directors, while the governance and compensation proposals generally warrant support due to a responsive pay structure and meaningful shareholder rights improvements being implemented this year.